Skip to main content
Log in

A Head-to-Head Comparison of Periprocedural Coagulability Under Anticoagulation with Rivaroxaban Versus Dabigatran in Patients Undergoing Ablation of Atrial Fibrillation

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objectives

Two new oral anticoagulants, rivaroxaban and dabigatran, with no need for anticoagulation monitoring, are available for patients with atrial fibrillation (AF). We aimed to compare their anticoagulant effects and safety when used during the AF ablation periprocedural period.

Methods

Patients undergoing AF ablation were randomly assigned to receive rivaroxaban 15 mg once daily (N = 30) or dabigatran 110 mg twice daily (N = 30). Rivaroxaban was withheld on the morning of the day before the ablation, and dabigatran was discontinued from the evening of the day before the procedure. Both anticoagulants were then resumed after haemostasis of the access site. D-dimer levels were measured just before the ablation, at the end of the ablation, and at 24 h and 48 h after the procedure.

Results

The baseline D-dimer levels were identical in both groups. However, D-dimer levels increased more markedly following the ablation procedure in patients receiving rivaroxaban than in those receiving dabigatran (mean ± standard deviation from 0.62 ± 0.16 to 1.09 ± 0.38 μg/mL vs from 0.59 ± 0.08 to 0.75 ± 0.17 μg/mL; p < 0.0001). The rate of rebleeding from the access site was similar in patients receiving rivaroxaban and those receiving dabigatran (33 vs 27 %; p = 0.78).

Conclusion

As compared with dabigatran, rivaroxaban may increase the risk of hypercoagulability when used during the periprocedural period of AF ablation, suggesting a potential rebound effect of rivaroxaban or a mismatch between its half-life and dose regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  PubMed  CAS  Google Scholar 

  2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  PubMed  CAS  Google Scholar 

  3. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(632–696):e21.

    PubMed  Google Scholar 

  4. Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:172–9.

    Article  PubMed  Google Scholar 

  5. Hori M, Matsumoto M, Tanahashi N, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation-subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013;77:632–8.

    Article  PubMed  CAS  Google Scholar 

  6. Hori M, Connolly SJ, Ezekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-analysis in Japanese population in RE-LY trial. Circ J. 2011;75:800–5.

    Article  PubMed  CAS  Google Scholar 

  7. Ouyang F, Bänsch D, Ernst S, et al. Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation. 2004;110:2090–6.

    Article  PubMed  Google Scholar 

  8. Habara S, Dote K, Kato M, et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J. 2007;28:2217–22.

    Article  PubMed  CAS  Google Scholar 

  9. Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55:2225–31.

    Article  PubMed  CAS  Google Scholar 

  10. Vene N, Mavri A, Kosmelj K, et al. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003;90:1163–72.

    PubMed  CAS  Google Scholar 

  11. Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34:1475–80.

    Article  PubMed  CAS  Google Scholar 

  12. Lee DS, Dorian P, Downar E, et al. Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation? Europace. 2001;3:195–200.

    Article  PubMed  CAS  Google Scholar 

  13. Bulava A, Slavík L, Fiala M, et al. Endothelial damage and activation of the hemostatic system during radiofrequency catheter isolation of pulmonary veins. J Interv Card Electrophysiol. 2004;10:271–9.

    Article  PubMed  Google Scholar 

  14. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995;91:1929–35.

    Article  PubMed  CAS  Google Scholar 

  15. Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 1996;92:479–85.

    Article  PubMed  CAS  Google Scholar 

  16. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin. 2006;22:471–81.

    Article  PubMed  CAS  Google Scholar 

  17. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013;61:651–8.

    Article  PubMed  CAS  Google Scholar 

  18. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  PubMed  CAS  Google Scholar 

  19. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011;9:12–9.

    Article  PubMed  CAS  Google Scholar 

  20. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180–7.

    Article  PubMed  CAS  Google Scholar 

  21. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation—regulatory considerations. N Engl J Med. 2011;365:1557–9.

    Article  PubMed  CAS  Google Scholar 

  22. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401–6.

    Article  PubMed  Google Scholar 

  23. Hoke M, Koppensteiner R, Schillinger M, et al. D-dimer testing in the diagnosis of transfemoral pseudoaneurysm after percutaneous transluminal procedures. J Vasc Surg. 2010;52:383–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank John Martin for his grammatical assistance.

Conflict of Interest Disclosure Statement

The authors have no conflicts of interest that are directly relevant to the content of this article.

Funding Statement

This work was not supported by any external funding.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akinori Sairaku.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sairaku, A., Yoshida, Y., Ando, M. et al. A Head-to-Head Comparison of Periprocedural Coagulability Under Anticoagulation with Rivaroxaban Versus Dabigatran in Patients Undergoing Ablation of Atrial Fibrillation. Clin Drug Investig 33, 847–853 (2013). https://doi.org/10.1007/s40261-013-0134-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-013-0134-5

Keywords

Navigation